Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia

Illingworth, 1985, Hyperlipidemia and coronary heart disease, 21

Lipid Research Clinics Program, 1984, The Lipid Research Clinics coronary primary prevention trial results. (1) Reduction in incidence of coronary heart disease, JAMA, 251, 351, 10.1001/jama.1984.03340270029025

Kane, 1986, Treatment of hypercholesterolemia, Annu Rev Med, 37, 427, 10.1146/annurev.me.37.020186.002235

Illingworth, 1987, Lipid lowering drugs: indications and optimum therapeutic use, Drugs, 33, 259, 10.2165/00003495-198733030-00003

Spengel, 1981, Superiority of partial ileal bypass over cholestyramine in reducing cholesterol in familial hypercholesterolemia, Lancet, 2, 768, 10.1016/S0140-6736(81)90183-5

Kane, 1984, Normalization of low density lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen, N Engl J Med, 304, 251, 10.1056/NEJM198101293040502

Illingworth, 1981, Colestipol plus nicotinic acid in treatment of heterozygous familial hypercholesterolemia, Lancet, 1, 296, 10.1016/S0140-6736(81)91910-3

1985, 253, 2080

Brown, 1983, Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic, J Clin Invest, 72, 743, 10.1172/JCI111044

Endo, 1976, Competitive inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase by ML236A and ML236B, fungal metabolites having hypocholesterolemic activity, FEBS Lett, 72, 323, 10.1016/0014-5793(76)80996-9

Alberts, 1980, Mevinolin: a highly potent competitive inhibitor of 3-hydroxy-3-methyl glutaryl coenzyme A reductase and a cholesterol lowering agent, 77, 3957

Kathawala, 1986, SRI-62320, an HMG CoA reductase inhibitor more potent than compactin (abstr), 28

Havel, 1986, Functional activities of hepatic lipoprotein receptors, Annu Rev Physiol, 48, 119, 10.1146/annurev.ph.48.030186.001003

Grundy, 1985, Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia, J Lipid Res, 26, 1464, 10.1016/S0022-2275(20)34252-8

Vega, 1986, Mevinolin effectively treats hyperlipidemia of the nephrotic syndrome (abstr), Arteriosclerosis, 6, 551A

1974

Warnick, 1978, A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high density lipoprotein cholesterol, J Lipid Res, 19, 65, 10.1016/S0022-2275(20)41577-9

Mabuchi, 1981, Effects of an inhibitor of 3-hydroxy-3-methyl glutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia, N Engl J Med, 305, 478, 10.1056/NEJM198108273050902

Yamamoto, 1980, Therapeutic effects of ML236B in primary hypercholesterolemia, Athersclerosis, 35, 259, 10.1016/0021-9150(80)90124-0

Illingworth, 1984, Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia, J Clin Invest, 74, 1972, 10.1172/JCI111618

1986, Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study, JAMA, 256, 2829, 10.1001/jama.1986.03380200067023

Mol, 1986, Effects of synvinolin (MK733) on plasma lipids in familial hypercholesterolemia, Lancet, 2, 936, 10.1016/S0140-6736(86)90598-2

Weisweiler, 1986, Colestipol plus fenofibrate vs synvinolin in familial hypercholesterolemia, Lancet, 2, 1212, 10.1016/S0140-6736(86)92214-2

Kazumi, 1986, Effects of CS514: a new inhibitor of HMG CoA reductase on plasma lipids, lipoproteins in patients with primary hypercholesterolemia, Horm Metab Res, 18, 654, 10.1055/s-2007-1012398

Hoeg, 1986, Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperipoproteinemia, Am J Cardiol, 57, 933, 10.1016/0002-9149(86)90733-2

Parker, 1984, Plasma mevalonate as a measure of cholesterol synthesis in man, J Clin Invest, 75, 795, 10.1172/JCI111495

Illingworth, 1986, Comparative efficacy of once versus twice dairy mevinolin in the therapy of familial hypercholesterolemia, Clin Pharmacol Ther, 40, 338, 10.1038/clpt.1986.185

Illingworth, 1987, Lovastatin (mevinolin) in the therapy of post-transplant hyperlipidemia (abstr), Clin Res, 572A

Golper, 1987, Effective and safe short term improvement in nephrotic hypercholesterolemia with the HMG CoA reductase inhibitor mevinolin (abstr), Kidney Int, 31, 200

East, 1986, Preliminary report; treatment of type III hyperlipoproteinemia with mevinolin, Metabolism, 35, 97, 10.1016/0026-0495(86)90106-X

Mabuchi, 1983, Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia, N Engl J Med, 308, 609, 10.1056/NEJM198303173081101

Illingworth, 1984, Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia, Ann Intern Med, 101, 598, 10.7326/0003-4819-101-5-598

Grundy, 1985, Influence of combined therapy with mevinolin and interruption of bile acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia, Ann Intern Med, 103, 339, 10.7326/0003-4819-103-3-339

Vega, 1987, Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol, JAMA, 1, 33, 10.1001/jama.1987.03390010037024

Illingworth, 1984, Hypercholesterolemia persisting after distal ileal bypass. Response to mevinolin, Ann Intern Med, 100, 850, 10.7326/0003-4819-100-6-850

Thompson, 1986, Efficacy of mevinolin as djuvant therapy for refractory familial hypercholesterolemia, Q J Med, 232, 803

Hoeg, 1986, The effects of mevinolin and neomycin alone and in combination on plasma lipid and lipoprotein concentrations in type II hyperlipoproteinemia, Atherosclerosis, 60, 209, 10.1016/0021-9150(86)90167-X

Lees, 1986, Therapy of hypercholesterolemia with mevinolin and other lipid lowering drugs (abstr), Arteriosclerosis, 6, 544A

Witztum, 1987, Intensive drug therapy of hypercholesterolemia, Am Heart J, 113, 603, 10.1016/0002-8703(87)90640-5

Illingworth, 1987, Specific inhibitors of cholesterol biosynthesis as hypocholesterolemic agents in humans: mevinolin and compactin, 231

Illingworth, 1985, The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia, 82, 6291

Achor, 1961, Cutaneous side effects from use of triparanol (MER29): preliminary data on icthiosis, 36, 217

Laughlin, 1962, Cataracts in patients treated with triparanol, JAMA, 181, 339, 10.1001/jama.1962.03050300059020a

Brown, 1980, Multivariant feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth, J Lipid Res, 21, 507, 10.1016/S0022-2275(20)42221-7

Pappu, 1987, The influence of lovastatin on 24 hour urinary excretion of mevalonic acid in familial hypercholesterolemia (abstr), Clin Res, 625A

Kovanen, 1981, Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog, 78, 1194

Bilheimer, 1983, Mevinolin and colestipol stimulate receptor mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes, 80, 4124

Ma, 1986, Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptors in livers of hamsters and rabbits, 83, 8370

Havel, 1987, A multicenter study of lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia, Ann Intern Med, 10.7326/0003-4819-107-5-609

Kajinami, 1986, Dose dependent reduction of serum lipid, lipoprotein and apoprotein levels by CS514, a new competitive inhibitor of HMG CoA reductase in familial hypercholesterolemic patients in a multicentered trial (abstr), 27